Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
BLQ Study: A Study of a Protease Inhibitor With Fuzeon (Enfuvirtide) in Treatment-Experienced Patients With HIV-1.
Phase 4
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2006-05-17
- Last Posted Date
- 2016-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 142
- Registration Number
- NCT00326963
A Study of Treatment With NeoRecormon (Epoetin Beta) in Patients With Chronic Renal Anemia
Phase 3
Completed
- Conditions
- Anemia
- Interventions
- Drug: epoetin beta [NeoRecormon]
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 605
- Registration Number
- NCT00321919
A Study of P38 Inhibitor (4) in Patients With Active Rheumatoid Arthritis (RA) on Stable Methotrexate Therapy
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: P38 Inhibitor (4) 50mgDrug: P38 Inhibitor (4) 25mgDrug: P38 Inhibitor (4) 300mgDrug: P38 Inhibitor (4) 75mgDrug: P38 Inhibitor (4) 150mgDrug: Placebo
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 374
- Registration Number
- NCT00316771
A Study to Evaluate the Long-Term Safety and Tolerability of GK Activator (2) in Patients With Type 2 Diabetes.
Phase 2
Completed
- Conditions
- Diabetes Mellitus Type 2
- Interventions
- Drug: GK Activator (2)
- First Posted Date
- 2006-04-21
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 259
- Registration Number
- NCT00316758
A Study of P38 Inhibitor (4) Monotherapy in Patients With Active Rheumatoid Arthritis
Phase 2
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- Drug: P38 Inhibitor (4)Drug: Placebo
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 204
- Registration Number
- NCT00303563
A Study of Bone Turnover Markers in Post-Menopausal Women With Osteoporosis Treated With Monthly Boniva (Ibandronate)
Phase 4
Completed
- Conditions
- Post Menopausal Osteoporosis
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-05-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 67
- Registration Number
- NCT00303485
A Study of Beta-Lactam in Hospitalized Patients With Skin and Skin Structure Infections
Phase 2
Completed
- Conditions
- Soft Tissue Infections
- Interventions
- Drug: beta-lactamDrug: Standard care
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 313
- Registration Number
- NCT00303589
IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients
- First Posted Date
- 2006-02-22
- Last Posted Date
- 2018-03-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 326
- Registration Number
- NCT00294515
- Locations
- 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸Robert Wood Johnson Uni Hospital; Anesthesia, New Brunswick, New Jersey, United States
🇺🇸Hackensack University Medical Center, Hackensack, New Jersey, United States
Fludarabine and Cyclophosphamide With or Without Rituximab in Patients With Previously Untreated Chronic B-Cell Lymphocytic Leukemia
Phase 3
Completed
- Conditions
- Leukemia
- Interventions
- First Posted Date
- 2006-01-25
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 817
- Registration Number
- NCT00281918
- Locations
- 🇩🇪
Praxis Fur Hamatologie und Onkologie Ahaus, Ahaus, Germany
🇩🇪Hamatologische/Onkologische Gemeinschaftspraxis - Augsburg, Augsburg, Germany
🇩🇪Onkologische Schwerpunktpraxis Bielefeld, Bielefeld, Germany
A Study of MabThera (Rituximab) in Patients With Advanced Non-Hodgkin's Lymphoma
Phase 3
Completed
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- Drug: Standard chemotherapy
- First Posted Date
- 2005-12-23
- Last Posted Date
- 2015-07-23
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 360
- Registration Number
- NCT00269113
© Copyright 2025. All Rights Reserved by MedPath